GLP 1 Drugs and Wet AMD Risk: What Patients Should Know

June 2025 — Emerging Research Links GLP 1 Medications to Higher Wet AMD Risk

New data raises questions about ocular side effects from popular medications like Ozempic, Wegovy, and Mounjaro—especially when used long-term.
________________________________________

📊 What the Research Found

A population-based study from Ontario, Canada (2020–2023) tracked over 139,000 adults with type 2 diabetes:
• 46,334 had used GLP 1 receptor agonists (mostly semaglutide) for ≥6 months
• 92,668 had never used them
Key findings:
• GLP 1 users were more than twice as likely to develop wet AMD overall
• Risk increased to over 3× for those on the medication for 30+ months
• Despite the relative increase, absolute rates were low—0.2% vs. 0.1%

https://www.healthline.com/health-news/glp-1-drugs-age-related-macular-degeneration-risk?utm

https://medicalxpress.com/news/2025-06-semaglutide-linked-neovascular-macular-degeneration.html?utm
________________________________________

🧐 What It Means for You

Consideration Explanation
🔄 Association ≠ Causation Experts caution that factors like smoking or UV exposure weren’t fully accounted for health.com

🩺 Still rare Only 2 additional cases per 1,000 people using GLP 1s
🎯 Dose-dependent effect Risk grows with longer duration of use
________________________________________

👓 What Patients Should Carefully Monitor

• Maintain annual eye exams—especially if you’re 60+ with diabetes
• Be alert for new visual symptoms: distorted lines, blind spots, glare
• Talk to your endocrinologist and ophthalmologist if you’re taking GLP 1s long-term
________________________________________

🔍 Expert Guidance

• The American Association of Clinical Endocrinology doesn’t recommend stopping GLP 1s but advises informed discussions https://www.health.com/ozempic-wet-amd-study-11750409?utm
• The American Academy of Ophthalmology encourages closer retinal monitoring when using GLP 1s https://www.beckershospitalreview.com/glp-1s/semaglutide-tied-to-increased-risk-of-eye-disease-4-study-takeaways/?utm
________________________________________

✅ Bottom Line

• New research shows a 2×–3× relative increase in wet AMD risk among long-term GLP 1 users
• But the overall incidence remains low
• The benefits of GLP 1s—for weight, glucose control, and heart health—likely still outweigh this small risk
• Still, regular eye exams and open communication between doctors are essential
💡 If you’re taking Ozempic, Wegovy, Mounjaro, or other GLP 1 medications, talk to your healthcare providers about personalized screening—a proactive approach can help preserve both your health and your vision.
________________________________________

Ozempic Users May Face Higher Risk of a Serious Eye Disease